[
  {
    "cui": "C0409651",
    "cui_name": "Seropositive rheumatoid arthritis",
    "incidence_per_100k": 25.0,
    "prevalence_per_100k": null,
    "metric_type": "incidence",
    "total_cases_per_year": 2000000,
    "confidence": 0.72,
    "is_subtype": true,
    "parent_disease": "Rheumatoid arthritis",
    "reasoning": "Seropositive RA (RF+ and/or anti-CCP+) represents ~65-70% of RA cases. Global RA incidence ~35-40 per 100k; seropositive proportion estimated at ~25 per 100k. Moderate confidence due to geographic variation and varying classification criteria across studies.",
    "data_quality": "strong",
    "geographic_variation": "high",
    "year_specific": false,
    "data_year": 2005,
    "source": "Kvien TK et al. (2005). Epidemiology of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, et al., eds. Rheumatology (3rd ed.). St. Louis: Mosby; Smolen JS et al. (2016). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 75(1):3-13",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/26738871/",
    "source_type": "literature"
  }
]
